ARWR Stock Cash Flow Statements

Arrowhead Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Arrowhead Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2013-05-07	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-30	2006-09-30	2006-06-30	2006-03-31	2005-12-31

cash flows from operating activities:
net income	-178,652,000	-173,977,000	-126,996,000	-135,376,000	-111,015,000	-104,125,000	47,676,000	-41,811,000	-85,942,000	-72,046,000	44,366,000	-62,872,000	-63,374,000	-29,924,000	-26,818,000	-20,732,000	-48,432,715	-13,611,213	-19,835,570	-2,673,728	11,704,905	20,335,709	23,896,982	12,037,253	-10,761,271	-15,606,018	-14,884,311	-13,198,878	-10,731,886	-5,519,742	-6,042,559	-12,086,108	-22,221,986	-19,420,742	-20,815,860	-19,264,414	-24,743,136	-15,936,052	-28,686,412	-22,575,282	-22,430,532	-11,626,449	-10,685,732	-6,940,018	-4,780,727	-5,600,749	-8,239,061	-5,584,114	-2,686,799	-2,946,938	-2,013,414	2,699,383	-1,231,430	-2,314,216	-1,816,429	-3,460,028	-2,528,617	-5,289,279	-8,030,468	-8,658,278	-7,502,163	-5,694,815	-5,233,774	-7,572,591	-12,477,548	-6,173,809	-3,707,170	-8,779,523	-3,974,148	-3,106,585	-3,136,953
adjustments to reconcile net income to net cash flow from operating activities
stock-based compensation	13,043,000	17,050,000	17,750,000	19,694,000	18,181,000	19,947,000	20,612,000	19,390,000	29,196,000	33,390,000	33,803,000	24,504,000	34,622,000	18,549,000	15,358,000	8,144,000	15,873,325	10,046,208	12,971,703	4,491,752	5,116,448	1,957,993	2,601,348	2,717,534	2,636,488	2,268,765	1,456,813	2,092,541	2,009,694	1,713,228	1,744,231	2,424,442	4,047,849	2,750,785	2,416,839	2,380,343	3,526,888	2,486,074	2,205,079	2,014,856	1,937,909	2,038,682	521,138	355,107	395,675	404,216	415,920	169,390	251,878	297,970	346,707	334,577	397,667	542,792	302,072	697,399	555,562	695,275	727,934	617,384	1,028,516	851,906	689,591	683,717	526,855
depreciation and amortization	6,223,000	4,782,000	4,525,000	4,263,000	3,859,000	3,276,000	2,669,000	2,689,000	2,660,000	2,594,000	2,594,000	2,573,000	2,504,000	1,997,000	1,918,000	1,848,000	1,774,391	1,536,401	1,371,588	1,259,884	1,082,375	1,003,450	1,175,967	1,177,352	1,228,395	1,176,241	1,153,466	1,141,173	1,154,525	1,162,660	1,187,644	1,185,611	843,584	818,200	803,912	794,349	855,551	741,058	449,559	290,039	270,417	276,054	403,405	448,765	449,597	447,169	423,415	423,947	454,444	64,936	66,472	14,199	122,370	146,904	174,304	202,080	265,672	239,487	287,365	283,645	267,048	297,510	285,178	286,179	252,591				229,469
amortization of note premiums/discounts	-1,757,000			-835,000	-987,000	-948,000
realized loss on investments
non-cash interest expense on liability related to the sale of future royalties	7,978,000	5,093,000	7,245,000	5,367,000	5,262,000	5,158,000	5,057,000	2,849,000
non-cash interest expense on credit facility	16,405,000
changes in operating assets and liabilities:
accounts receivable	-7,476,000				1,246,000	68,188,000	-29,867,000	-38,157,000	-1,171,000	1,078,000	-1,167,000	10,105,000	-9,583,000	283,000	8,048,000	-8,157,000	20,846,891	-20,426,793	79,527	-683,937	1,382,750	11,378,229	-10,253,761	-2,841,204	-312,400	1,312	133,644	-82,134	869,516	-356,488	-520,825	15,000																																0
prepaid expenses and other assets	-1,406,000
accounts payable	23,379,000	11,187,000	4,061,000	-12,463,000	27,997,000	-1,687,000	8,760,000	-2,072,000	-3,026,000	-4,709,000	6,535,000	-5,389,000	-580,000	4,738,000	472,000	-2,002,000	2,755,041	-9,343,823	1,216,159	4,551,611	3,019,679	568,054	125,601	1,130,491	640,366	355,300	-3,896,615	1,630,533	843,092	635,533	-340,607	-4,648,013	1,641,138	-1,597,128	2,253,576	257,216	169,444	-74,021	-1,013,092	3,415,473	421,346	-321,018	-610,284	62,180	-68,459	-116,387	183,768	87,047	137,448	75,525	253,565	-1,917,244	1,745,233	-351,228	-121,604	-385,262	-603,283	90,337	569,489	-203,551	-45,459	279,566	-468,162	-102,339	963,708	98,421	-454,871	632,965	-666,122	384,573	18,949
accrued expenses	-10,965,000	13,097,000	-419,000	408,000	17,117,000	-4,803,000	-20,076,000	-7,203,000	16,037,000	-1,986,000	5,989,000	-2,290,000	-4,160,000	11,411,000	3,397,000	-1,126,000	2,043,713	5,370,374	-1,210,896	-4,213,695	5,927,314	-1,136,584	1,149,061	-3,489,712	5,669,379	-1,734,121	-368,049	-2,550,703	4,936,050	78,106	-3,564,937	-1,850,996	3,856,467	-624,946	-157,851	-3,945,503	6,590,817	-712,583	-116,775	-1,325,675	3,018,404	184,320	56,648	87,377	111,865	-327,748	115,330	-9,996	408,783	543,901	94,486	-2,554,449	2,368,905	-215,289	-8,866	-429,560	-95,079	-344,209	542,312	-293,361	195,809	91,035	-149,006	89,558	126,398	75,585	-423,560	-507,029	552,018	-4,501	372,694
deferred revenue	-20,289,000	0	0	-866,000	-16,039,000	-14,009,000	-76,156,000	-22,979,000	-25,401,000	-32,174,000	-27,487,000	-27,439,000	11,866,000	-35,726,000	259,665,000	-12,547,000	-6,983,287	-6,900,403	-20,859,364	-28,770,642	-15,136,090	-22,681,877	-37,474,302	158,096,440	-942,600	-621,800	-310,000	-3,394,740	-8,638,265	-8,511,185	-8,345,105	25,652,536																												0	0	-37,999	-60,571	-280,075				-259,463	228,213	-37,500	-37,500
operating lease	-1,162,000	-537,000	621,000	3,796,000
other	-41,000								-3,607,000	2,682,000	68,000	922,000	1,929,000	-205,000	358,000	-855,000	924,235	578,371	-227,708	953,189	1,642,983	-297,283	25,105	-265,842	-102,290	-115,569	-240,341	43,907	-9,831	-125,469	96,019	-235,471	106,894	-166,031	147,491	42,789	-72,024	-2,786
net cash from operating activities	-154,720,000	-115,418,000	-92,377,000	-117,840,000	-25,257,000	-21,446,000	-31,671,000	-75,516,000	-68,667,000	-68,847,000	62,730,000	-61,347,000	-24,117,000	-29,610,000	263,873,000	-38,922,000	-10,850,025	-33,427,150	-27,583,937	-23,530,458	13,809,906	10,526,762	-19,586,508	168,284,763	-2,680,318			-14,690,480	-9,203,474	-10,409,632	-14,326,057	10,000,191	-10,181,379	-18,350,203	-14,747,835	-21,148,069	-12,020,234	-13,117,797	-16,369,578	-24,200,006																											-5,090,439				-3,188,513
capex	-2,364,000	-14,449,000	-34,075,000	-68,656,000	-63,907,000	-46,605,000	-27,314,000	-38,911,000	-32,711,000	-9,536,000	-4,752,000	-5,778,000	-8,199,000	-3,931,000	-7,166,000	-4,271,000	-1,884,352	-2,138,260	-3,609,386	-4,319,714	-7,830,940	-3,223,497	-209,301	-737,487	-709,473			-135,414	-107,444	-1,157,596	-1,356,505	-5,296,653	-2,712,489	-647,114	-94,022	-406,612	-834,961	-283,588	-297,118	-554,945																											-115,579				-96,644
free cash flows	-157,084,000	-129,867,000	-126,452,000	-186,496,000	-89,164,000	-68,051,000	-58,985,000	-114,427,000	-101,378,000	-78,383,000	57,978,000	-67,125,000	-32,316,000	-33,541,000	256,707,000	-43,193,000	-12,734,377	-35,565,410	-31,193,323	-27,850,172	5,978,966	7,303,265	-19,795,809	167,547,276	-3,389,791			-14,825,894	-9,310,918	-11,567,228	-15,682,562	4,703,538	-12,893,868	-18,997,317	-14,841,857	-21,554,681	-12,855,195	-13,401,385	-16,666,696	-24,754,951																											-5,206,018				-3,285,157
cash flows from investing activities:
purchases of property and equipment	-2,364,000	-14,449,000	-34,075,000	-68,656,000	-63,907,000	-46,605,000	-27,314,000	-38,911,000	-32,711,000	-9,536,000	-4,752,000	-5,778,000	-8,199,000	-3,931,000	-7,166,000	-4,271,000	-1,884,352	-2,138,260	-3,609,386	-4,319,714	-7,830,940	-3,223,497	-209,301	-737,487	-709,473	-198,060	-378,305	-135,414	-107,444	-1,157,596	-1,356,505	-5,296,653	-2,712,489	-647,114	-94,022	-406,612	-834,961	-283,588	-297,118	-554,945	-465,375	-644,215	-116,215
purchases of investments	-96,724,000	-118,629,000			-12,157,000	-41,456,000	-81,329,000	-111,199,000	0	-75,000,000	-82,516,000	-65,875,000	-145,508,000	-55,195,000
proceeds from sales and maturities of investments	240,478,000	140,027,000	75,120,000	133,495,000				69,416,000
net cash from investing activities	141,390,000	6,949,000	-268,937,000	64,839,000	30,509,000	-9,905,000	-36,065,000	-80,694,000	36,445,000	61,278,000	-69,755,000	-33,385,000	-118,245,000	-19,541,000	-34,050,000	30,158,000	-65,894,401	-6,033,806	-178,129,843	9,280,286	16,829,060	14,398,503	-11,217,301	-67,756,269	3,247,016	-28,854,640	16,815,695	1,356,966	-4,218,751	-12,926,204	-26,202,610	-5,296,653	-1,712,489	9,460,886	3,105,978	2,593,388	5,844,843	3,976,784	8,798,882	-4,499,671																		50,554	671,900		1,956,119	-187,926	6,846,143	-192,658	-410,565	-37,569	5,020,767	14,582,756	3,686,165	-18,633,784	-177,159
cash flows from financing activities:
proceeds from the exercises of stock options	223,000	387,000	1,512,000	267,000	821,000	1,136,000	520,000	576,000	855,000	600,000	1,846,000	1,885,000	815,000	2,755,000	2,633,000	5,102,000	1,004,476	2,132,846	1,330,023	3,001,554
proceeds from the issuance of common stock, net of offering costs		0
proceeds from the sales of future royalties
proceeds from the issuance of warrants	0
payments of debt issuance costs	0
proceeds from the issuance of common stock	0																0	0	2,235	250,476,739	10	0	0	60,521,729	0	0			0	-272,818	191,937	12,500,000
repayments of credit facility	-50,000,000
proceeds from visirna credit agreement
net cash from financing activities	-42,679,000	50,387,000	430,777,000	267,000	152,000	1,805,000	520,000	250,576,000	855,000	60,600,000	1,846,000	1,885,000	815,000	2,755,000	2,633,000	5,102,000	1,004,476	2,132,846	1,332,258	253,478,293	1,833,415	2,767,274	2,670,036	59,111,274	1,571,129	1,454,074	56,901,531	26,292	-122,343	0	142,069	12,035,583	53,643,773	2,205,013	-222,384	-494,585	136,932	-53,475	26,766	180,298																2,550,281	-204,593	-200,555	4,319,871	15,842,874	0	0	290,027	16,625	15,250,115	4,000	316,202	1,304,058	33,479	19,545,000	4,000
net increase in cash, cash equivalents and restricted cash	-56,009,000		69,463,000	-52,734,000			-67,216,000	94,366,000
effect of exchange rate on cash, cash equivalents and restricted cash	93,000	-223,000	26,000	58,000	153,000	-79,000	-74,000	-122,000
cash, cash equivalents and restricted cash:
beginning of period	0	0	0	110,891,000		0	0	108,005,000
end of period	-55,916,000	-58,305,000	69,489,000	58,215,000	5,557,000	-29,625,000	-67,290,000	202,249,000
supplementary disclosure of cash flows:
interest paid	0																				0	0	0	-27,437	-41,952	-42,892	-43,815	-44,722	-45,614	-46,489	-47,349	-48,195	-2,381	-3,109	-8,851	3,054	3,276	3,498	3,717	3,938	4,157	4,373	9,496	10,714	11,114			12,553	10,300	0	0			499	13,118	11,917	24,086	24,140	28,124
income taxes paid	0	-48,000																				0											0	0
supplemental disclosure of non-cash investing activities:
capital expenditures included in accrued expenses	-12,000	-356,000	-4,025,000	11,290,000
amortization (accretion) of note premiums/discounts		6,990,000						690,000
realized gain on investments		0	0	-80,000
proceeds from the sale of future royalties					0	0	0	250,000,000
net decrease in cash, cash equivalents and restricted cash
prepaid expenses and other current assets			-895,000	-1,748,000	-16,310,000	7,604,000	9,780,000	10,529,000	-10,415,000	-962,000	-6,733,000	-1,181,000	2,535,000	-682,000	980,000	-3,193,000	475,823	-909,807	-1,331,140	1,377,660	-1,317,285	-952,943	-1,319,375	-120,912	-537,087	-369,309	1,254,785	-29,223	-362,042	652,444	1,497,086	1,027,021	-133,308	-245,586
supplemental disclosure of noncash investing activities:
income taxes (paid) refunded				-999,000
adjustments to reconcile net income to net cash flow from operating activities:
net gain from investments
proceeds from investment in joint venture									0
beginning or period
supplementary disclosures:
unrealized losses on marketable securities
operating lease liabilities						-47,000	646,000	559,000
proceeds from maturities of investments						78,156,000
proceeds from additional tenant improvement allowance
amortization of note premiums																																	30,556	21,886	71,057	108,403	165,410	276,750
proceeds from sale of investments									69,156,000	145,814,000	17,513,000	38,268,000	35,462,000	39,585,000																																0	0	0	509,009	404,380	540,611					0	0	0	700,000									-1	1	0	80,145
net increase in cash and cash equivalents
effect of exchange rate on cash and cash equivalents
cash and cash equivalents at beginning of period									0	0	0	184,434,000	0	0	0	143,583,000	0	0	0	221,804,128
cash and cash equivalents at end of period									-31,434,000	53,031,000	-5,179,000	91,587,000	-141,547,000	-46,396,000	232,456,000	139,921,000	-75,739,950	-37,328,110	-204,381,522	461,032,249
unrealized (gains) losses on marketable securities										1,602,000
amortization/(accretion) of note premiums/discounts										1,684,000	609,000	-280,000		-51,000
net increase in cash										53,031,000	-5,179,000	-92,847,000	-141,547,000	-46,396,000	232,456,000	-3,662,000	-75,739,950	-37,328,110	-204,381,522	239,228,121		27,692,539	-28,133,773	159,639,768	2,137,827	-41,809,731	58,273,772	-13,307,222	-13,544,568	-23,335,836	-40,386,598	16,739,121	41,749,905	-6,684,304	-11,864,241	-19,049,266	-6,038,459	-9,194,488	-7,543,930	-28,519,379	-5,839,123	-4,498,127	40,598,980	382,451	-446,256		-1,312,471	-3,178,014	-734,263	3,191,081	-473,291	-677,205	-1,380,358	-2,136,283	1,789,372	111,039	-1,648,155	-4,079,502	-2,456,743	-3,729,895	-5,698,821	-5,902,016	1,304,220	-6,673,783	9,202,179	-6,675,133	246,530	11,332,253	103,304	-2,520,598	-3,361,671
amortization/(accretion) of note premiums																-302,000	-127,442	233,535	241,764	177,448	386,827	352,014	486,866	-156,637	-199,298	236,034	238,556	107,783	96,522	-75,654
principal payments on notes payable																					0	0	-1	-2,415,149	-53,520	-52,580	95,384	-197,790
income taxes (paid)/refunded
proceeds from sale of marketable securities																34,429,000		9,545,320	6,002,967	13,600,000	24,660,000	17,622,000	9,987,000	2,252,219	8,865,000	13,500,000	17,194,000	6,510,420	958,753				1,000,000	10,108,000	3,200,000	3,000,000	6,679,804	7,260,372	9,096,000	3,054,774	5,000,296	1,580,586	4,045,956
change in value of derivatives																									0	0	18,598	-450,739	629,151	-63,065	27,383	-1,483,831	534,074	113,359	-369,935	23,524	-422,864	104,713	-168,974	-2,382,142	321,324	-758,468	3,519,579	29,402	-44,275	-160,553	-915,387	622,144	66,904	110,029	-373,734
payment of taxes for net share settled restricted stock unit issuances
purchases of marketable securities																		-13,440,866			0	0	-20,995,000	-69,271,001	-4,908,511	-42,156,580	0	-5,018,040	-5,070,060	-15,058,571
payments of taxes for net share settled restricted stock unit issuances																									0	0			-21,698	0	0	-417,140	0	0	-193,653	-440,534
proceeds from the exercises of warrants and stock options																					1,833,405	2,767,274	2,670,037	1,004,694	1,624,649	1,506,654	275,779	224,082	0
income tax credits refunded																													0	0			0	0
income tax paid																									0	0			0	0																										0	0	0	4,800	0	0	0	4,800				3,200			0	7,900
cash and restricted cash at beginning of period
cash and restricted cash at end of period
computers, office equipment and furniture																						0	-12,290	600,334	0	0	0	600,334				601,159	-2,882	26,092	6,140	413,565				374,535
research equipment																						1,542,203	-335,101	11,356,568	405,963	170,985	378,305	9,796,374				8,729,818	191,295	435,343	79,931	6,783,831				5,010,151
software																						0	-79,290	225,092	3,847	16,751	0	132,078				107,871	-40,727	11,140	0	110,428				69,623
leasehold improvements																						2,732,432	199,787	12,269,261	27,770	0	0	12,208,380				12,000,074	896,650	7,813,711	7,951	3,167,053				3,117,537
total gross fixed assets																						4,274,635	-226,894	24,451,255	437,580	187,736	378,305	22,737,166				21,438,922	1,044,336	8,286,286	94,022	10,474,877				8,571,846
less: accumulated depreciation and amortization																						-578,343	-315,452	-10,530,588	-531,394	-740,810	-728,358	-7,804,800				-5,273,263	2,067,604	-393,093	-378,805	-5,808,466				-4,447,405
property and equipment																						3,696,292	-542,346	13,920,667	-93,814	-553,074	-350,053	14,932,366				16,165,659	3,111,940	7,893,193	-284,783	4,666,411				4,124,441				0	7,215,206	0	0	0	7,215,206															0
cash at beginning of period																							0	30,133,213	0	0	0	24,838,567	0	0	0	85,366,448	0	0	0	81,214,354	0	0	0	132,510,610	0	0	19,114,444	0	3,377,288	0	0	0	7,507,389	0	0	0	6,847,162	0	2,020,224	0	0	0	10,093,585	0	0	0	24,120,097	0	0	0	28,020,304	0	0	0	22,467,016
cash at end of period																							-28,133,773	189,772,981	2,137,827	-41,809,731	58,273,772	11,531,345	-13,544,568	-23,335,836	-40,386,598	102,105,569	41,749,905	-6,684,304	-11,864,241	62,165,088	-6,038,459	-9,194,488	-7,543,930	103,991,231	-5,839,123	-4,498,127	59,713,424	382,451	2,931,032	1,094,647	-1,312,471	-3,178,014	6,773,126	3,191,081	-473,291	-677,205	5,466,804	-2,136,283	3,809,596	111,039	-1,648,155	-4,079,502	7,636,842	-3,729,895	-5,698,821	-5,902,016	25,424,317	-6,673,783	9,202,179	-6,675,133	28,266,834	11,332,253	103,304	-2,520,598	19,105,345
contingent consideration - fair value adjustments
noncash impairment expense
property and equipment purchased through tenant improvement allowance financing																																	0
property and equipment expenditures included in accounts payable and accrued expenses																																-1,041,276
net cash (used in) operating activities
(gain) loss on disposal of fixed assets																																							-45,576	26,381	0	0	53,562	54,932	-18,493
acquired-in-process research and development
proceeds from sale of fixed assets																																					0	0	0	500				8,036	121,418	265,275	18,509									-23,636
cash paid for acquisitions																																					0	-3,000,000
common stock issued to novartis for asset acquisition																																						0
principal payments on capital leases and notes payable																														0	-49,868	-47,277	-54,725	-54,498	-54,275	-54,051		-53,608	-3,386	-103,168
commercial notes																														11,844,262
total																														11,844,262
net income attributable to non-controlling interests
net income attributable to arrowhead																																					-24,743,136	-15,936,052	-28,686,412	-22,575,282	-22,430,442	-11,628,917	-10,628,312	-6,757,936	-4,614,159	-5,313,681	-7,991,510	-5,335,232	-2,485,505	-2,776,523	-1,819,917	2,905,237	-1,437,682	-2,004,106	-1,544,927
gain on debt extinguishment
noncash gain on equity investment
non-controlling interest																																									-90
purchase of marketable securities																																									0	0	-19,075,306
proceeds from the exercise of warrants and stock options																																	1,467,065	2,259,511			190,761	133	30,152	283,466	504,039
common stock issued to galloway limited in settlement of services agreement
receivables																																				-1,054,719				-127,000	0	0		115,266	-105,891	-6,295	19,580	-22,660	172,230				-4,528,308	-49,401	14,376	248,539	-227,002	90,355	-172,550	73,866	333,415	-91,529	-127,127	109,197	-383,061	35,017	36,997	-37,637	5,623	-5,500	-3,252
prepaid expenses																																				-490,057				-3,874,051	111,436	-57,640	-74,455	34,525	157,208	-185,749	32,559	-155,271	-30,070	93,820	47,954	-99,482	56,714
income from discontinued operations
acquired in-process research and development																																					0	0
noncash gain in equity investment
other receivables																																					-168,695	-340,895	-269,994	-9,506	492,119	93,374	-11,825			-2,111,702	1,871,747	-278,986	-419,238	-258,483	-82,208	-481,672	86,110	-144,804										0
other current assets																																					2,899,876	320,750						-201,877	-12,441	23,433			-1	1			96,363	-45,883
principal payments on capital leases																																									31,772	-52,730	-54,715	-53,497	-53,098	-52,701	-52,307	-51,658	-39,940
proceeds from issuance of common stock and preferred stock																																									-49
cash flows from discontinued operations:
operating cash flows																																												-336	-18	-55	677	-482	-420	-355	-56,959			18,095	-15,767
investing cash flows																																																						0	430,000
financing cash flows
net cash from discontinued operations:																																												-336	-18				-420	-355	-56,959			18,095	414,233
3,321,383 shares of common stock issued to novartis for asset acquisition
131,579 shares of common stock issued to galloway limited in settlement of services agreement
239,894 shares of common stock issued to roche for stock and asset acquisition
intangible assets - patents
intangible assets – license
acquired in-process research and development - pre-clinical candidates
total purchase consideration																																												0	5,268,814	84,935	0	0	5,183,879
amortization/accretion of note premiums/discounts																																								347,703
other liabilities																																								-802	98,737	209,849	-222,811	12,308	14,208													-173,994	5,544	-129,757	228,261	-322,465	64,758	751,502	325,071	-43,046	135,538	158,852	-135,535	-54,371	83,656
other investing activities																																								-7,000,000
cash flows from operating activities of continuing operations:
net (income) loss attributable to non-controlling interests																																									90
(income) income from discontinued operations																																												336	18	55	-677	482	220	362	68,742	-5,358,760	-2,953
realized and unrealized (gain) loss on investments																																														0	0	0	58,091	122,732
charge for bad debt allowance
(gain) loss on purchase of roche madison																																														0	0	0	-1,576,107
non-cash gain in equity investment																																									0
non-cash impairment expense																																														187,000
equity in income of unconsolidated affiliates																																												157,612	63,557		34,573	64,261	106,527
other assets																																									-1,885
net cash from operating activities of continuing operations																																									-10,919,806	-9,776,513	-7,022,332	-4,466,764	-3,837,586	-4,587,800	-3,889,848	-4,157,086	-2,705,356	-1,662,944	-967,034	-3,602,378	-1,423,637	-2,531,027	-1,617,843
cash flows from investing activities of continuing operations:
cash transferred in acquisitions/divestitures
net cash from investing activities of continuing operations																																									4,544,921	936,371	-15,145,565	1,146,188	111,979	178,364	-76,052	-201,288	539,620	404,380	536,817
cash flows from financing activities of continuing operations:
proceeds from sale of stock in subsidiary																																																0	8,000	-226				300,000		0	0	0	2,000,000	1	2,000,000	-3,000,000	10,013,897
net cash from financing activities of continuing operations																																									535,762	4,342,015	62,766,877	3,703,363	3,279,369	5,504,138	2,652,752	1,180,842	1,431,893	4,450,000	13,885	1,719,157	43,279	319,056	2,992,982
amortization (accretion) of note discounts																																										146,979	28,443	36,359	572	30,023	-26,918	2,502	3,783	4,549
amortized cost
net (income) loss attributable to noncontrolling interests
(gain) income from sale of subsidiary
stock issued for professional services
purchased in-process research and development
gain on sale of stock in subsidiary
noncontrolling interest																																											-57,420	-182,082	-166,568	-287,068	-247,551	-248,882	-201,294	-170,415	-193,497	-205,854	206,252	-310,110	-271,502
purchase of masa energy, llc																																																												0
minority equity investment
cash paid for interest in insert																																																																0	0	0	-5,150,000
cash obtained from interest in insert																																																																0	0	0	5,150,000
proceeds from sale of subsidiaries
payment for patents																																																																						43,217	-160,660
restricted cash
proceeds from issuance of common stock, preferred stock and warrants																																											62,821,592
proceeds from issuance of calando debt
taxes paid																																																		0	0	0	742,500
purchase of property and equipment																																												-22,029	-9,439	-86,911	-115,559	-207,816	-69,424	0	-3,794					0	-12,145	0	-28,100	-175,175	-153,256	-187,926	-167,754	-192,658	-410,565				-223,062
proceeds from issuance of common stock and warrants																																												3,756,860	3,332,467	5,556,839	2,705,059	1,232,500	1,463,833	4,450,226	-1,705,273	1,719,157	43,279	93,901	3,205,896					6,968,986	0	0	290,027	16,625	15,250,115				33,479
net (income) loss attributable to nonconrolling interests																																											57,420		166,568				201,294			205,854	-206,252
write down of note receivable
purchase of marketable securities - us treasury bills
proceeds from sale of marketable securities - us treasury bills
current assets																																												0	432,709	0	0	0	432,709	-164,000	-237,000	133,000	289,000
intangible assets																																												0	1,174,935	84,935	0	0	1,090,000															4,200,000
other noncurrent assets																																												0	6,264	0	0	0	6,264
current liabilities																																												0	-414,122	0	0	0	-414,122
noncurrent liabilities																																												0	-1,570,072	0	0	0	-1,570,072
gain on purchase																																												0	-1,576,106	0	0	0	-1,576,106
deposits																																																						0	14,808	7,966	111,200	28,995	-3,520	-116,931	-25,000	70,696	-25,520	-30,365	-42,390	16,514	48,158	2,956	19,004	-19,380	-53,670
purchase of marketable securities—us treasury bills
notes payable
proceeds from sale of marketable securities—us treasury bills
loss on disposal of fixed assets																																														169,616
equity in (income)loss of unconsolidated affiliates
cash transferred in acquisition/divestitures																																														0	20,998	0	100,035
proceeds from issuance of stock in subsidiary																																														0
net increase(decrease) in cash
stock issued as gift
stock issued for in-process research and development																																																								630,982				0
purchased in-process research and development - nanoconduction
accrued severance and other liabilities																																															-106,463	490,683	346,551	-32,047	32,349	35,661	-20,212	-13,486	78,935	604,068
net cash from discontinued operations																																															677
cash paid for interest
cash paid for income taxes
loss on sale/donation of fixed assets																																																								-3,375
purchased in-process research and development—nanoconduction
gain on renegotiation of accrued severance
non-cash (gain) income from equity investment																																																		66,813	70,367	74,826	-48,826
cash transferred in sale of subsidiary																																																		0	0
non-current assets																																																		-15,000	-8,000
liabilities																																																		112,000	60,000	436,000	647,000
equity																																																		-291,000	-305,000	-326,000	-227,000
revenue																																																					495,000
operating expenses																																																					275,000
cash flows used in operating activities
cash flows used in investing activities																																																					-15,000
cash flows from financing activities
realized and unrealized (gain) loss on investment																																																								0	0	0	-700,000										-124,549
amortization of note discount
gain from sale of subsidiary																																																												0
stock issued as gift to caltech
stock issued as gift to rice university																																																												0	0
change in percentage of ownership in subsidiary
change in value of derivative liability																																																					-465,270
cash paid for interest in calando																																																								0												-2,109,332	-890,668
cash paid for interest in unidym																																																								-1,037,003	-875,000			0	-2,000,000	0	-3,000,000
cash obtained from interest in calando																																																								0												3,000,000	0
cash obtained from interest in unidym																																																								1,037,003	875,000			0	2,000,000
proceeds from sale of subsidiary																																																												0
net cash from (used) in investing activities of continuing operations
non-current assets 529																																																					131,000
cash flows from operating activities																																																					294,000
plus: net income attributable to noncontrolling interests																																																						310,110
(income)/income from discontinued operation																																																						-18,095
realized and unrealized gain on investment
(gain)/loss on disposal of fixed assets
non-cash income from equity investment																																																						53,813	48,638	48,090	48,302	60,030	69,382
increase of cash flow from:
other prepaid expenses																																																						97,904	110,156	133,698	1,661	-85,817	15,317	156,126	-68,434	-175,625	114,178	174,318	-158,774	-225,902	116,356	-4,942	18,538	-256,780	72,516
cash paid for interest in nanotechnica
cash paid for interest in aonex																																																																				0	0
cash paid/obtained for interest in tego
cash obtained from interest in nanotechnica
cash obtained from interest in aonex																																																																				0	0
cash paid/obtained from interest in tego
payments of capital leases																																																						-74,845	-212,914	-208,712	-204,593	-200,555	-196,596
change in value of derivative liabillity
exercise prices
5.04																																																							1,397,500						0	0	1,397,500			0	1,397,500
7.06																																																							712,362						0	0	712,362
2.00																																																							3,863,989
0.50																																																							9,684,522
0.51																																																							5,083,430
1.65
total warrants outstanding
plus: net income attributable to nonconrolling interests																																																							271,502
income from discontinued operation																																																							-414,233
prepaid research expense																																																											-9,319	25,006	33,499	26,625	414,481	-160,020	135,596	-171,642	62,075	-4,197	86,731	-143,987	-212,501
minority interests																																																												-2,970,483	-1,994,088	-1,144,995	-1,335,976	-3,683,681	-681,467	-1,934,532	-453,352	285,644	-221,298	-584,499	-796,437
gain on negotiation of accrued expenses
change in operating assets and liabilities
preferred stock liability																																																																0	0	0	-1,162,000
net cash from (used) in investing activities																																																								-23,636
proceeds of issuance of calando debt																																																								0	0	0	2,516,467
•
purchased-in-process research and development—nanoconduction
net cash (used) in operating activities
cash paid for interest in tego																																																									0	0	1,700,000	0	100,000	0	-2,500,000
cash obtained from interest in tego																																																									0	0	-1,700,000	0	-100,000	0	2,500,000
subscription receivable																																																											-750,000
sale of property and equipment
purchased-in-process research and development - nanoconduction
net cash provided (used) in operating activities																																																											-7,448,514	-8,383,697	-7,654,940	-5,714,090	-5,831,950	-6,497,750	-5,637,371				-3,616,340
decrease/increase in:
net cash (used) in investing activities
cash and cash equivalents																																																																0
rent deposit and other assets																																																																0
total assets acquired
liabilities assumed
consideration transferred
series b preferred share of unidym
series a preferred share of unidym
goodwill expensed to in-process research & development																																																																	0
cni purchase expensed to in-process research & development
impairment of goodwill
proceeds from sale of marketable securities -us treasury bills
proceeds from sale of insert therapeutic’s stocks																																																																	0	0	5,136,346
total assets
stockholders equity
goodwill impaired
proceeds from sale of investments payment for patents
realized (gain) loss on investment																																																																							-3,266
compensation expense related to stock option issuance																																																																			480,812	371,939	365,776	352,986	278,777
depreciation & amortization																																																																			230,578				228,474
purchase of property & equipment																																																																			-115,579				-96,644
cash obtained from interest in nanopolaris
proceeds from issuance of common stock & warrants																																																																			316,202				4,000
exercise price
loss on disposal of assets
realized/unrealized (gain) loss on investment
purchase of marketable securities – us treasury bills
proceed from sale of marketable securities – us treasury bills
cash paid for interest in nanopolaris

We provide you with 20 years of cash flow statements for Arrowhead Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Arrowhead Pharmaceuticals stock. Explore the full financial landscape of Arrowhead Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Arrowhead Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.